ABSTRACT
Vaccination against SARS-COV-2 has been the most important strategy for preventing infection and controlling pandemics of Coronavirus disease 2019 (COVID-19). But there is a lack of research on the pandemics in postoperative patients with breast cancer. We conducted a web-based questionnaire survey on SARS-CoV-2 vaccination in these populations. Univariate and multivariable logistic regression was used to estimate the associations. Among 947 valid online questionnaires, 341 (36.0%) accepted SARS-CoV-2 vaccination, while 606 (64.0%) were not. There were significant differences in age, current treatment, the time since surgery, and the symptoms of anxiety and depression between the two groups. We identified current treatment (odds ratio, OR = 0.51 for endocrine therapy; 95% CI: 0.29–0.89), the time since surgery (OR = 22.49 for 1–2 years; 95% CI: 12.31–41.10; OR = 8.49 for 2–5 years ; 95% CI: 4.98–14.46; OR = 1.79 for > 5 years ; 95% CI: 1.11–2.89), and the symptoms of depression (OR = 2.48; 95% CI: 1.19–5.15) as significant factors for unvaccination. The overall incidence of adverse reactions was 43.1%, and the most common local and systemic adverse reactions were pain at the injection site (28.4%) and fatigue (8.8%), respectively. Postoperative patients with breast cancer have a lower rate of vaccination for SARS-CoV-2. Receiving treatment, a shorter time since surgery and symptom of depression were associated with unvaccination. But, about 76.6% of the unvaccinated participants were willing to be vaccinated when their breast cancer was stable. More importantly, a favorable safety profile of the vaccines is indicated.